natgillin/translations-raw huggingface dataset:
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Quadramet 1.3 GBq/mL solution for injection Samarium (153Sm) lexidronam pentasodium 
IME ZDRAVILA IN POT(I) UPORABE Quadramet 1,3 GBq/ml raztopina za injiciranje (153Sm)samarij-leksidronam, pentanatrijeva sol Za intravensko uporabo
The administration of radiopharmaceuticals creates risks for other persons from external radiation or contamination from spills of urine, vomiting etc. 
Aplikacija radiofarmakov predstavlja tveganje izpostavljenosti sevanju drugih oseb ali kontaminaciji zaradi razlitja urina, bruhanja ipd. Zaradi tega morate upoštevati nacionalne predpise glede previdnostnih ukrepov za zaščito pred ionizirajočimi sevanji.
Solution for injection in a single-dose vial. 
FARMACEVTSKA OBLIKA IN VSEBINA Raztopina za injiciranje v enoodmerni viali.
The other ingredients are total EDTMP (as EDTMP.H2O), calcium-EDTMP sodium salt (as Ca), total sodium (as Na), water for injections. 
Pomožne snovi so skupni EDTMP (v obliki EDTMP.H2O), kalcij-EDTMP natrijeva sol (v obliki Ca), skupni natrij (kot Na), voda za injekcije
Quadramet 1.3 GBq/mL solution for injection 
Quadramet 1,3 GBq/ml raztopina za injiciranje
ATC Code: V10BX02 
Farmakoterapevtska skupina: razni radioterapevtiki za lajšanje bolečin, Oznaka ATC: V10BX02
Total EDTMP (as EDTMP.H2O) Calcium-EDTMP sodium salt (as Ca) Total sodium (as Na) Water for injections 
Skupni EDTMP (v obliki EDTMP.H2O) Kalcij-EDTMP natrijeva sol (v obliki Ca) Skupni natrij (kot Na) Voda za injekcije
QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of solution contains 1.3 GBq Samarium (153Sm) lexidronam pentasodium at the reference date (corresponding to 20 to 80 µg/ml of samarium per vial) Samarium specific activity is approximately 16 - 65 MBq/µg of samarium. 
En ml raztopine vsebuje 1,3 GBq (153Sm)samarij-leksidronam, pentanatrijeve soli, na referenčni datum (ustreza 20 do 80 µg/ml samarija na vialo)
NAME OF THE MEDICINAL PRODUCT Quadramet 1.3 GBq/mL solution for injection. 
IME ZDRAVILA Quadramet 1,3 GBq/ml raztopina za injiciranje
How to store Quadramet 
Shranjevanje zdravila Quadramet
The active substance is samarium (153Sm) lexidronam pentasodium. 
Zdravilna učinkovina je (153Sm)samarij-leksidronam, pentanatrijeva sol.
Tc)-labelled biphosphonates on bone scan. 
(99mTc) označene bifosfonate.
Verification of the dose to be administered and patient identification are necessary prior to administration of Quadramet. 
Pred aplikacijo zdravila Quadramet morate verificirati odmerek in identificirati bolnika.
Total EDTMP (as EDTMP.H2O) Calcium-EDTMP sodium salt (as Ca) Total sodium (as Na) Water for Injections 
SEZNAM POMOŽNIH SNOVI skupni EDTMP (v obliki EDTMP.H2O) kalcij-EDTMP natrijeva sol (v obliki Ca) skupni natrij (kot Na) voda za injekcije
Method and route of administration Quadramet is to be administered by slow injection into a vein. 
Quadramet se injicira počasi v veno.
Please refer to the SmPC (SmPC should be included in the box) 
Glejte Povzetek glavnih značilnosti zdravila (Povzetek glavnih značilnosti zdravila naj bi bil vključen v škatlo).
Samarium (153Sm) lexidronam pentasodium. 
(153Sm)samarij-leksidronam, pentanatrijeva sol
Decreases in white blood cell and platelet counts and anaemia were observed in patients receiving Quadramet. 
Pri bolnikih, ki so prejemali Quadramet, so opazili zmanjšanje števila levkocitov in trombocitov ter pojav anemije.
1.3 GBq/ml at reference date. 
Quadramet 1,3 GBq/ml raztopina za injiciranje.
Liver 
Sevanje
Repaglinide Accord is taken before meals, normally up to 15 minutes before each main meal. 
Zdravilo Repaglinid Accord se jemlje pred obroki, običajno največ 15 minut pred vsakim glavnim obrokom.
It is available as round tablets (0.5 mg, 1 mg and 2 mg). 
Na voljo je v obliki okroglih tablet (0,5 mg, 1 mg in 2 mg).
Repaglinide Accord is not recommended for patients below 18 years of age because of a lack of information on safety and effectiveness in this age group. 
Uporaba zdravila Repaglinid Accord pri bolnikih, mlajših od 18 let, zaradi pomanjkanja informacij o varnosti in učinkovitosti v tej starostni skupini ni priporočljiva.
The European Commission granted a marketing authorisation valid throughout the European Union for Repaglinide Accord on 22 December 2011. 
Evropska komisija je dovoljenje za promet z zdravilom Repaglinid Accord, veljavno po vsej Evropski uniji, odobrila dne 22. decembra 2011.
This means that Repaglinide Accord is similar to a ‘reference medicine' already authorised in the European Union (EU) called NovoNorm. 
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu NovoNorm.
The full EPAR for Repaglinide Accord can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Repaglinid Accord je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
For more information about treatment with Repaglinide Accord, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Repaglinid Accord preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
EPAR summary for the public repaglinide 
Povzetek EPAR za javnost repaglinid
What are the benefits and risks of Repaglinide Accord? 
Kakšne so koristi in tveganja, povezani z zdravilom Repaglinid Accord?
Other information about Repaglinide Accord 
Druge informacije o zdravilu Repaglinid Accord
This is a summary of the European public assessment report (EPAR) for Repaglinide Accord. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Repaglinid Accord.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Repaglinide Accord. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Repaglinid Accord, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Repaglinide Accord is a ‘generic medicine'. 
Zdravilo Repaglinid Accord je „generično zdravilo“.
Because Repaglinide Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Repaglinid Accord generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
The CHMP concluded that, in accordance with EU requirements, Repaglinide Accord has been shown to have comparable quality and to be bioequivalent to the reference medicine. 
CHMP je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Repaglinid Accord primerljivo raven kakovosti kot referenčno zdravilo ter da mu je biološko enakovredno.
Repaglinide Accord is a medicine that contains the active substance repaglinide. 
Repaglinid Accord je zdravilo, ki vsebuje zdravilno učinkovino repaglinid.
A doctor should regularly test the patient's blood glucose to find the lowest effective dose. 
krvi mora zdravnik redno preverjati, da določi najmanjši učinkoviti odmerek.
Repaglinide Accord is used in patients who have type 2 diabetes (non-insulin-dependent diabetes). 
Zdravilo Repaglinid Accord se uporablja pri bolnikih s sladkorno boleznijo tipa 2 (sladkorno boleznijo, ki ni odvisna od insulina).
Because Repaglinide Accord is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine. 
Ker je zdravilo Repaglinid Accord generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu.
The Committee recommended that Repaglinide Accord be given marketing authorisation. 
Odbor je priporočil, da se za zdravilo Repaglinid Accord dobri dovoljenje za promet.
Page 2/2 
Raven bolnikove glukoze v stran 2/2
Repaglinide Accord helps the pancreas to produce more insulin at mealtimes and is used to control type 2 diabetes. 
Zdravilo Repaglinid Accord spodbuja trebušno slinavko, da v času obroka tvori več insulina, zato se uporablja za nadzor sladkorne bolezni tipa 2.
Repaglinide Accord may also be used with metformin (another anti-diabetes medicine) in type 2 diabetes patients whose blood glucose levels are not satisfactorily controlled on metformin alone. 
Zdravilo Repaglinid Accord se lahko uporablja tudi z metforminom (drugim zdravilom za sladkorno bolezen) pri bolnikih s sladkorno boleznijo tipa 2, pri katerih samo z metforminom ne moremo zadovoljivo nadzorovati ravni glukoze v krvi.
Why has Repaglinide Accord been approved? 
Zakaj je bilo zdravilo Repaglinid Accord odobreno?
What is Repaglinide Accord? 
Kaj je zdravilo Repaglinid Accord?
How has Repaglinide Accord been studied? 
Kako je bilo zdravilo Repaglinid Accord raziskano?
What is Repaglinide Accord used for? 
Za kaj se zdravilo Repaglinid Accord uporablja?
blood glucose levels are usually controlled well on diet, but are experiencing temporary loss of blood glucose control. 
Zdravilo Repaglinid Accord se lahko uporablja tudi pri bolnikih s sladkorno boleznijo tipa 2, pri katerih so ravni glukoze v krvi po navadi dobro nadzorovane z dieto, vendar doživljajo obdobja prehodne izgube nadzora.
How is Repaglinide Accord used? 
Kako se zdravilo Repaglinid Accord uporablja?
How does Repaglinide Accord work? 
Kako zdravilo Repaglinid Accord deluje?
1 produced in E. coli cells by recombinant DNA technology 2 adsorbed on aluminium hydroxide (0.5 mg Al3+) 
1 izdelano v celicah E. coli s tehnologijo rekombinantne DNA 2 adsorbirano na aluminijev hidroksid (0,5 mg Al3+)
3 NHBA (Neisserial Heparin Binding Antigen), NadA (Neisseria adhesin A), fHbp (factor H binding protein) 
3 NHBA (Neisserial heparin vezavni antigen), NadA (Neisseria adhezin A), fHbp (faktor H vezavna beljakovina)
--1 One dose (0.5 ml) contains: Recombinant Neisseria meningitidis group B NHBA fusion protein 1, 2, 3 
--1 En odmerek (0,5 ml) vsebuje: rekombinantna fuzijska beljakovina NHBA iz Neisseria meningitidis skupine B 1, 2, 3
Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254 measured as amount of total protein containing the PorA P1.4 2 
sev NZ98/254, izmerjen kot količina skupnih beljakovin, ki vsebuje PorA P1.4 2
Recombinant Neisseria meningitidis group B NadA protein 1, 2, 3 
rekombinantna beljakovina NadA iz Neisseria meningitidis skupine B 1, 2, 3
Recombinant Neisseria meningitidis group B fHbp fusion protein 1, 2, 3 
rekombinantna fuzijska beljakovina fHbp iz Neisseria meningitidis skupine B 1, 2, 3
10 pre-filled syringes without needles 
10 napolnjenih injekcijskih brizg brez igel
10 pre-filled syringes with needles 
10 napolnjenih injekcijskih brizg z iglami
1 pre-filled syringe without needles 
1 napolnjena injekcijska brizga brez igel
1 pre-filled syringe with needles 
1 napolnjena injekcijska brizga z iglami
The name of the medicine was changed to Granupas on 15 May 2014. 
Ime zdravila je bilo 15. maja 2014 spremenjeno v Granupas.
They should be given a total of 150 mg per kilogram body weight every day, split into two doses. 
Prejeti morajo skupno 150 mg na kilogram telesne mase vsak dan, razdeljeno na dva odmerka.
The first of these involved 166 patients with tuberculosis aged between 15 to 30 years. 
V prvo študijo je bilo vključenih 166 bolnikov s tuberkulozo, starih od 15 do 30 let.
In children and adolescents, the daily dose depends on their weight. 
Pri otrocih in mladostnikih je dnevni odmerek odvisen od njihove telesne mase.
What measures are being taken to ensure the safe and effective use of Granupas? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Granupas?
This is a summary of the European public assessment report (EPAR) for Granupas. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Granupas.
Other information about Granupas 
Druge informacije o zdravilu Granupas
PAS has been used for many years in the EU for the combination treatment of tuberculosis. 
Para-aminosalicilna kislina se v EU že več let uporablja za kombinirano zdravljenje tuberkuloze.
The most common side effects with Granupas (which may affect up to 1 in 10 people) are abdominal pain (stomach ache), vomiting, nausea, bloating, diarrhoea and soft stools, giddiness, disturbance in gait and balance, and allergic skin reactions and rash. 
Najpogostejši neželeni učinki zdravila Granupas (ki se lahko pojavijo pri največ 1 bolniku od 10) so bolečine v trebuhu (želodcu), bruhanje, slabost, napenjanje, driska in mehko blato, vrtoglavica, motnje hoje in ravnotežja ter alergijske kožne reakcije in izpuščaji.
Granupas must not be taken by patients with severely reduced kidney function. 
Zdravila Granupas ne smejo uporabljati bolniki z močno zmanjšanim delovanjem ledvic.
A dosing spoon is used to measure small doses for young children. 
Za odmerjanje manjših odmerkov za majhne otroke se uporablja merilna žlička.
A risk management plan has been developed to ensure that Granupas is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Granupas je bil pripravljen načrt obvladovanja tveganj.
The summary of the opinion of the Committee for Orphan Medicinal Products for Granupas can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation. 
Povzetek mnenja Odbora za zdravila sirote za zdravilo Granupas je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Because the number of patients with tuberculosis is low in the EU, the disease is considered ‘rare', and Granupas was designated an ‘orphan medicine' (a medicine used in rare diseases) on 17 December 
Ker je bolnikov s tuberkulozo v EU malo, velja ta bolezen za redko, zato je bilo zdravilo Granupas 17. decembra 2010 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
Previously known as Para-aminosalicylic acid Lucane 
Predhodno znan kot para-aminosalicilna kislina Lucane
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Granupas's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Granupas večje od z njim povezanih tveganj, in priporočil, da se zdravilo odobri za uporabo v EU.
What benefits of Granupas have been shown in studies? 
Kakšne koristi je zdravilo Granupas izkazalo v študijah?
The applicant also provided published data on the doses of PAS to be used in children. 
Predlagatelj je predložil tudi objavljene podatke o odmerkih para-aminosalicilne kisline za uporabo pri otrocih.
What are the risks associated with Granupas? 
Kakšna tveganja so povezana z zdravilom Granupas?
For more information about treatment with Granupas, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Granupas preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What is Granupas and what is it used for? 
Kaj je zdravilo Granupas in za kaj se uporablja?
The patients were treated for 3 months with either PAS or another medicine called streptomycin, or with a combination of PAS and streptomycin, and then followed up for 3 extra months. 
Bolniki so tri mesece prejemali zdravljenje s para-aminosalicilno kislino ali drugim zdravilom, ki se imenuje streptomicin, ali kombinacijo para-aminosalicilne kisline in streptomicina, ter so jih nato spremljali še dodatne tri mesece.
In the second main study involving 341 patients aged over 12 years, PAS in combination with isoniazid was compared with isoniazid alone. 
V drugi glavni študiji, v katero je bilo vključenih 341 bolnikov, starih več kot 12 let, so paraaminosalicilno kislino v kombinaciji z izoniazidom primerjali z izoniazidom v monoterapiji.
The recommended dose for adults is one sachet three times a day. 
Priporočeni odmerek za odrasle je ena vrečka trikrat na dan. Zdravljenje običajno traja dve leti.
Multi-drug resistance is when the bacteria causing tuberculosis (Mycobacterium tuberculosis) are resistant to treatment with at least isoniazid and rifampicin, two standard tuberculosis medicines. 
Odpornost proti več zdravilom pomeni, da so bakterije, ki povzročajo tuberkulozo (Mycobacterium tuberculosis), odporne najmanj na zdravljenje z izoniazidom in rifampicinom, tj. dvema standardnima zdraviloma proti tuberkulozi.
It is not intended to provide practical advice on how to use Granupas. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
The full EPAR and risk management plan summary for Granupas can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Granupas sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Why is Granupas approved? 
Zakaj je bilo zdravilo Granupas odobreno?
For practical information about using Granupas, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Granupas naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Granupas, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti tega zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
For the full list of all side effects reported with Granupas, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Granupas, glejte navodilo za uporabo.
The benefits in combination with other tuberculosis treatments were shown in published studies presented by the company, two of which were considered to be the main studies for the application. 
Koristi v kombinaciji z drugimi zdravili proti tuberkulozi so bile prikazane v objavljenih študijah, ki jih je družba predstavila.
It is used in combination with other medicines to treat adults and children from 28 days of age who have multi-drug resistant tuberculosis when combinations without this medicine cannot be used, either because the disease is resistant to them or because of their side effects. 
Uporablja se v kombinaciji z drugimi zdravili za zdravljenje tuberkuloze, odporne proti več zdravilom, pri odraslih in otrocih, starejših od 28 dni, kadar zaradi odpornosti bolezni ali neželenih učinkov ni mogoče uporabiti drugih kombinacij brez tega zdravila.
The Committee noted that the active substance, PAS, has been shown to be beneficial when used in combination with other medicines to treat tuberculosis and that it helps reduce the emergence of resistance to other medicines. 
Odbor je ugotovil, da se je zdravilna učinkovina, para-aminosalicilna kislina, izkazala kot koristna, kadar se uporablja v kombinaciji z drugimi zdravili za zdravljenje tuberkuloze, in da pomaga zmanjšati pojav odpornosti proti drugim zdravilom.
The European Commission granted a marketing authorisation valid throughout the European Union for Para-aminosalicylic acid Lucane on 7 April 2014. 
Evropska komisija je dovoljenje za promet z zdravilom , veljavno po vsej Evropski uniji, izdala 7. aprila 2014.
Granupas is a tuberculosis medicine that contains the active substance para-aminosalicylic acid (PAS). 
Zdravilo Granupas je zdravilo za zdravljenje tuberkuloze, ki vsebuje zdravilno učinkovino paraaminosalicilna kislina (PAS).
PAS had been widely used in the past for combination treatment but was largely discontinued due to adverse effects on the stomach. 
Para-aminosalicilno kislino so v preteklosti pogosto uporabljali za kombinirano zdravljenje, vendar so njeno uporabo precej zmanjšali zaradi neželenih učinkov na želodec.
The Committee also noted that the World Health Organization continues to recommend PAS as an option to be used in combination with other medicines for treating multi-drug resistant tuberculosis. 
Odbor je prav tako ugotovil, da Svetovna zdravstvena organizacija še naprej priporoča paraaminosalicilno kislino kot možnost za uporabo v kombinaciji z drugimi zdravili za zdravljenje tuberkuloze, odporne proti več zdravilom.
PAS is similar to a chemical (para-aminobenzoic acid) that is used by the bacteria to make folic acid needed for new bacteria to grow. 
Para-aminosalicilna kislina je podobna kemični snovi (paraaminobenzojski kislini), s pomočjo katere bakterija tvori folno kislino, ki je potrebna za rast novih bakterij.
It is available as 4 g sachets containing ‘gastroresistant' granules that allow the active substance to reach the intestine without being released in the stomach, thus reducing side effects in the stomach. 
Na voljo je v 4-gramskih vrečkah, ki vsebujejo „gastrorezistentna zrnca“, zasnovana tako, da zdravilna učinkovina doseže črevesje, ne da bi se sprostila v želodcu, s čimer se zmanjšajo neželeni učinki v želodcu.
The CHMP noted that Granupas contains gastro-resistant granules, designed to allow PAS to reach the intestine without being released in the stomach, and thus reduce the potential for side effects. 
CHMP je ugotovil, da zdravilo Granupas vsebuje gastrorezistentna zrnca, ki so zasnovana tako, da lahko para-aminosalicilna kislina doseže črevesje, ne da bi se sprostila v želodcu, s tem pa se zmanjša možnost neželenih učinkov.
para-aminosalicylic acid 
Granupas para-aminosalicilna kislina
After 12 months, 90% of patients in the combination group did not have the bacteria in their phlegm compared with 51% of patients given a comparable dose of isoniazid alone. 
Po 12 mesecih bakterije v sluzi ni imelo 90 % bolnikov v skupini, ki je prejemala kombinirano zdravljenje, v primerjavi z 51 % bolnikov, ki so prejemali primerljiv odmerek samega izoniazida.
The active substance, PAS, is a ‘bacteriostatic agent', which means that it works by stopping the growth of M. tuberculosis bacteria. 
Zdravilna učinkovina, para-aminosalicilna kislina, je bakteriostatik, kar pomeni, da deluje tako, da zaustavi rast bakterije M. tuberculosis.
By interfering and taking the place of this chemical in the processes that make folic acid, para-aminosalicylic acid reduces the amount of folic acid produced and thereby stops or slows the growth of M. tuberculosis. 
Para-aminosalicilna kislina v procesih tvorbe folne kisline vpliva na to kemično snov in jo nadomesti, s tem pa zmanjša količino nastale folne kisline in zaustavi ali upočasni rast bakterije M. tuberculosis.
PAS in combination with streptomycin also helped reduce the emergence of resistance to streptomycin: in 89% of patients receiving the combination the bacteria remained responsive to streptomycin, compared with 21% of patients who were given only streptomycin. 
Para-aminosalicilna kislina je v kombinaciji s streptomicinom pomagala zmanjšati tudi pojav odpornosti proti streptomicinu: bakterija je postala odzivna na streptomicin pri 89 % bolnikov, ki so prejemali kombinirano zdravljenje, v primerjavi z 21 % bolnikov, ki so prejemali samo streptomicin.
In addition, the PAS-isoniazid combination helped reduce the emergence of resistance to isoniazid: after 1 year, while 47% of patients in the isoniazid-only group had resistant bacteria the figure was only 8% in the combination group. 
Poleg tega je kombinacija para-aminosalicilne kisline in izoniazida pomagala zmanjšati pojav odpornosti proti izoniazidu: po enem letu je v skupini, ki je prejemala samo izoniazid, odpornost proti bakteriji razvilo 47 % bolnikov, v skupini, ki je prejemala kombinirano zdravljenje, pa samo 8 %.
How does Granupas work? 
Kako zdravilo Granupas deluje?